期刊
CLINICAL KIDNEY JOURNAL
卷 9, 期 3, 页码 411-417出版社
OXFORD UNIV PRESS
DOI: 10.1093/ckj/sfw024
关键词
acute kidney injury; immune-checkpoint blockade; interstitial nephritis
资金
- National Institutes of Health [T32DK007527]
- American Heart Association [12FTF120070328]
Immune-checkpoint inhibitors are emerging as revolutionary drugs for certain malignancies. However, blocking the co-inhibitory signals may lead to immune-related adverse events, mainly in the spectrum of autoimmune diseases including colitis, endocrinopathies and nephritis. Here, we report a case of a 75-year-old man with metastatic malignant melanoma treated with a combination of nivolumab (anti-PD1-antibody) and ipilimumab (anti-CTLA-4 antibody) who developed systemic rash along with severe acute tubulointerstitial nephritis after two doses of combination therapy. Kidney biopsy and peripheral blood immune profile revealed highly proliferative and cytotoxic T cell features. Herein, we discuss the pathophysiology and management of immune checkpoint blockade-related adverse events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据